Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGHTNASDAQ:FORANASDAQ:NRCNASDAQ:OABI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGHT8X8$1.77-2.2%$2.01$1.51▼$3.52$233.10M1.811.05 million shs456,797 shsFORAForian$2.02-6.5%$2.02$1.85▼$4.03$67.38M1.0417,039 shs5,583 shsNRCNational Research$11.36-4.3%$13.03$9.76▼$35.81$260.67M0.4194,443 shs79,862 shsOABIOmniAb$1.70-8.1%$2.51$1.66▼$4.96$207.63M0.06605,124 shs6.23 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGHT8X8+2.84%+11.04%-9.05%-39.06%-23.95%FORAForian-8.74%+3.83%+1.75%-12.66%-24.35%NRCNational Research+9.50%+11.04%-8.06%-27.31%-65.39%OABIOmniAb+2.78%+1.09%-23.55%-41.64%-59.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEGHT8X83.2885 of 5 stars4.01.00.00.02.52.51.9FORAForian2.5542 of 5 stars3.53.00.00.02.13.30.0NRCNational Research2.1709 of 5 stars0.03.02.50.03.50.81.3OABIOmniAb2.7646 of 5 stars3.51.00.00.02.43.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGHT8X8 2.00Hold$2.6650.12% UpsideFORAForian 3.00Buy$5.00147.52% UpsideNRCNational Research 0.00N/AN/AN/AOABIOmniAb 3.00Buy$7.00311.76% UpsideCurrent Analyst Ratings BreakdownLatest FORA, NRC, EGHT, and OABI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/24/2025EGHT8X8Rosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.30 ➝ $2.704/22/2025EGHT8X8Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$2.00 ➝ $1.504/16/2025EGHT8X8Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$2.60 ➝ $1.904/15/2025EGHT8X8MizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$2.50 ➝ $2.004/8/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/27/2025OABIOmniAbRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$7.00 ➝ $4.003/22/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/20/2025OABIOmniAbBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $6.003/19/2025OABIOmniAbHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/7/2025EGHT8X8Weiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGHT8X8$717.44M0.32$0.43 per share4.16$0.86 per share2.06FORAForian$20.15M3.13N/AN/AN/A∞NRCNational Research$143.06M1.82$1.05 per share10.81$2.02 per share5.62OABIOmniAb$26.39M7.87N/AN/A$2.69 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGHT8X8-$67.59M-$0.36N/A17.706.08-6.33%-1.45%-0.21%N/AFORAForianN/A-$0.09N/A∞N/AN/AN/AN/A5/13/2025 (Estimated)NRCNational Research$24.78M$1.0510.82∞N/A17.32%66.52%20.00%5/6/2025 (Estimated)OABIOmniAb-$50.62M-$0.60N/AN/AN/A-308.78%-20.97%-18.05%5/8/2025 (Estimated)Latest FORA, NRC, EGHT, and OABI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FORAForian$0.02N/AN/AN/A$5.37 millionN/A5/8/2025Q1 2025OABIOmniAb-$0.17N/AN/AN/A$4.49 millionN/A4/28/2025Q1 2025NRCNational ResearchN/A$0.25N/A$0.25N/A$33.55 million3/18/2025Q4 2024OABIOmniAb-$0.13-$0.12+$0.01-$0.12$10.13 million$10.80 million2/4/2025Q3 2025EGHT8X8$0.01$0.04+$0.03$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEGHT8X8N/AN/AN/AN/AN/AFORAForianN/AN/AN/AN/AN/ANRCNational Research$0.484.23%N/A45.71%N/AOABIOmniAbN/AN/AN/AN/AN/ALatest FORA, NRC, EGHT, and OABI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025NRCNational Researchquarterly$0.124.1%6/27/20256/27/20257/11/20253/24/2025NRCNational Researchquarterly$0.123.27%3/28/20253/28/20254/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGHT8X83.081.251.24FORAForianN/AN/AN/ANRCNational Research1.300.470.47OABIOmniAbN/A4.624.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGHT8X893.99%FORAForian19.25%NRCNational Research47.26%OABIOmniAb72.08%Insider OwnershipCompanyInsider OwnershipEGHT8X81.22%FORAForian31.30%NRCNational Research2.00%OABIOmniAb8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGHT8X82,220131.69 million130.09 millionOptionableFORAForian14031.19 millionN/AOptionableNRCNational Research49022.95 million23.01 millionOptionableOABIOmniAb7122.14 million129.07 millionOptionableFORA, NRC, EGHT, and OABI HeadlinesRecent News About These CompaniesCompanies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In GrowthApril 25, 2025 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Short Interest Up 21.3% in MarchApril 22, 2025 | marketbeat.comOmniAb, Inc. (NASDAQ:OABI) Shares Purchased by JPMorgan Chase & Co.April 22, 2025 | marketbeat.comOmniAb Announces Two New Appointments to its Board of DirectorsApril 21, 2025 | finance.yahoo.comOmniAb Appoints New Directors to BoardApril 21, 2025 | tipranks.comQ1 Earnings Estimate for OmniAb Issued By Leerink PartnrsApril 20, 2025 | marketbeat.comLeerink Partners Sticks to Their Buy Rating for OmniAb (OABI)April 20, 2025 | markets.businessinsider.comQ1 Earnings Forecast for OmniAb Issued By Leerink PartnrsApril 20, 2025 | americanbankingnews.comInsider Selling: OmniAb, Inc. (NASDAQ:OABI) Insider Sells 7,206 Shares of StockApril 9, 2025 | marketbeat.comInsider Selling: OmniAb, Inc. (NASDAQ:OABI) CEO Sells $38,764.00 in StockApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Has $985,000 Stock Position in OmniAb, Inc. (NASDAQ:OABI)April 9, 2025 | marketbeat.comOmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr Sells 19,382 SharesApril 9, 2025 | marketbeat.comOmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson Sells 11,963 SharesApril 3, 2025 | marketbeat.comKurt A. Gustafson Sells 11,963 Shares of OmniAb, Inc. (NASDAQ:OABI) StockApril 2, 2025 | insidertrades.comAnalyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI)March 29, 2025 | uk.finance.yahoo.comOmniAb price target lowered to $4 from $7 at RBC CapitalMarch 27, 2025 | markets.businessinsider.comOmniAb price target lowered to $4 from $8 at TD CowenMarch 21, 2025 | msn.comOmniAb price target lowered to $6 from $8 at BenchmarkMarch 21, 2025 | markets.businessinsider.comOmniAb, Inc. (NASDAQ:OABI) Director John L. Higgins Acquires 125,750 SharesMarch 21, 2025 | insidertrades.comOmniAb Stock Short Interest Report | NASDAQ:OABI | BenzingaMarch 19, 2025 | benzinga.comOmniAb reports Q4 EPS (12c), consensus (10c)March 19, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFORA, NRC, EGHT, and OABI Company Descriptions8X8 NASDAQ:EGHT$1.77 -0.04 (-2.21%) As of 04:00 PM Eastern8x8, Inc. engages in the provision of enterprise communication solutions. It offers solutions to the business services, education, financial services, government, healthcare, and manufacturing industries. The company was founded in February 1987 and is headquartered in Campbell, CA.Forian NASDAQ:FORA$2.02 -0.14 (-6.48%) As of 04:00 PM EasternForian Inc. provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions. The company's subscription and services-based solutions cover the life sciences, pharma services, and healthcare payer and provider industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania.National Research NASDAQ:NRC$11.36 -0.51 (-4.30%) As of 04:00 PM EasternNational Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.OmniAb NASDAQ:OABI$1.70 -0.15 (-8.11%) As of 04:00 PM EasternOmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
